http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Young Joo Park ),( Hyun Young Woo ),( Jeong Heo ),( Sang Gyu Park ),( Young Mi Hong ),( Ki Tae Yoon ),( Dong Uk Kim ),( Gwang Ha Kim ),( Hyung Hoi Kim ),( Geun Am Song ),( Mong Cho ) 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: Glecaprevir/pibrentasvir (G/P) is a pangenotypic direct-acting combination of antiviral agents used to treat chronic hepatitis C virus (HCV) infections. There are limited real-life data on G/P for Korean patients. We evaluated the real-life effectiveness and safety of G/P at single institution in Korea. Methods: This was a retrospective, observational, cohort study. The primary effectiveness endpoint was sustained virologic response at 12 weeks after treatment completion (SVR12). Safety and tolerability were also assessed. Results: Of 267 patients with chronic HCV infections who received G/P, females were 148 (55.4%) and the median age was 63.0 years (range: 25-87 years). Eighty-three (31.1%) had HCV genotype-1 and 182 (68.2%) had HCV-2. A total of 212 (79.4%) were HCV treatment-naive, 200 (74.9%) received the 8-week treatment, 13 (4.9%) received prior treatment for hepatocellular carcinoma, 37 (13.7%) had chronic kidney disease stage 3 or more, and 10 (3.7%) were receiving dialysis. Intention-to-treat (ITT) analysis indicated that 256 (95.9%) achieved SVR12. A modified ITT analysis indicated the SVR12 was 97.7% (256/262). Six patients failed therapy because of post-treatment relapse. The SVR12 was significantly lower in those who received prior sofosbuvir treatment (P=0.002) and those with detectable HCV RNA at week 4 (P=0.027). Seventy (26.2%) patients experienced at least one adverse event, most of which were mild. Conclusions: These real-life data indicated that G/P treatment of patients with HCV infections had high effectiveness and was well-tolerated, regardless of viral genotype and the presence of comorbidities.
( Young Joo Park ),( Hyun Young Woo ),( Jeong Heo ),( Sang Gyu Park ),( Young Mi Hong ),( Ki Tae Yoon ),( Dong Uk Kim ),( Gwang Ha Kim ),( Hyung Hoi Kim ),( Geun Am Song ),( Mong Cho ) 대한간학회 2021 Gut and Liver Vol.15 No.3
Background/Aims: Glecaprevir/pibrentasvir (G/P) is a combination of direct-acting antiviral agents that is an approved treatment for chronic infections by all six hepatitis C virus (HCV) genotypes. However, there are limited data on the effect of G/P in Korean patients in actual real-world settings. We evaluated the real-life effectiveness and safety of G/P at a single institution in Korea. Methods: This retrospective, observational, cohort study used sustained virologic response at 12 weeks after treatment completion (SVR12) as the primary effectiveness endpoint. Safety and tolerability were also determined. Results: We examined 267 individuals who received G/P for chronic HCV infections. There were 148 females (55.4%), and the overall median age was 63.0 years (range, 25 to 87 years). Eightythree patients (31.1%) had HCV genotype-1 and 182 (68.2%) had HCV-2. A total of 212 patients (79.4%) were HCV treatment-naïve, 200 (74.9%) received the 8-week treatment, 13 (4.9%) had received prior treatment for hepatocellular carcinoma, 37 (13.7%) had chronic kidney disease stage 3 or higher, and 10 (3.7%) were receiving dialysis. Intention to treat (ITT) analysis indicated that 256 (95.9%) achieved SVR12. A modified ITT analysis indicated that SVR12 was 97.7% (256/262). Six patients failed therapy because of posttreatment relapse. SVR12 was significantly lower in those who received prior sofosbuvir treatment (p=0.002) and those with detectable HCV RNA at week 4 (p=0.027). Seventy patients (26.2%) experienced one or more adverse events, and most of them were mild. Conclusions: These real-life data indicated that G/P treatment was highly effective and well tolerated, regardless of viral genotype or patient comorbidities. (Gut Liver 2021;15:440-450)
Introduction of familiy Eriocraniidae (Lepidoptera, Eriocranioidea) from Korea
Young-Gwang Song,Bong-Kyu Byun 한국응용곤충학회 2023 한국응용곤충학회 학술대회논문집 Vol.2023 No.10
좀날개나방과(Eriocraniidae)는 나비목 중 4번째로 분화한 분류군으로 잘 알려져 있으며, 현재 5속 29종으로 이루어져 있다. 성충의 머리에는 큰턱의 흔적기관이 남아있으며, 흡관이 관찰되어 흡관아목에 속한다. 출현시기 는 3~4월의 초봄에 나타나며, 주로 아침에 활동하는 것으로 알려져 있다. 국내에는 Eriocarnia 속에 속하는 자작나 무좀굴나방(Eriocrania sparrmannella) 한 종만이 알려져 있으며, 인근 국가의 분포 현황을 보았을 때 잠재적인 종이 분포할 것으로 예상된다. 본 연구에서는 Eriocraniidae의 서식환경 및 생태를 소개하여 추후 연구의 기틀을 마련하고자 한다.
Lee, Jung-Yong,Seo, Ju-Hee,Kim, Hyung Young,Jung, Young Ho,Kwon, Ji-Won,Kim, Byoung-Ju,Kim, Hyo Bin,Lee, So-Yeon,Jang, Gwang Cheon,Song, Dae Jin,Kim, Woo Kyung,Shim, Jung Yeon,Kim, Ha-Jung,Shin, Yee-J Informa Healthcare 2012 The Journal of asthma Vol.49 No.8
<P><I>Aims</I>. The aims of this study were (1) to determine the reference values for impulse oscillometry (IOS) and (2) to apply them to the evaluation of asthma in the general population of young Korean children. <I>Methods</I>. We performed a questionnaire survey and IOS measurements in 390 children aged 3-7 years in Seoul and Gyeonggi province, Korea, from July to August 2010. IOS measurements included respiratory resistance (Rrs) and respiratory reactance (Xrs) at 5, 10, 15, 20, 25, and 35 Hz, respiratory impedance (Zrs), and resonance frequency (RF) before and 15 min after inhalation of 200 μg salbutamol. To determine the reference values for IOS, 161 children defined as healthy controls were assessed. <I>Results</I>. The IOS measurements were presented as means and standard deviations. The reference equations for IOS variables were determined by multiple linear regression analysis taking into account their height, weight, and age (R5 = 2.242 - 0.008 × height (cm) - 0.005 × age (months), coefficients of determination (<I>R</I><SUP>2</SUP>) = 0.213). Height had the greatest correlation with IOS variables, similar to previous studies. Positive airway obstruction was defined as R5 greater than the 95th percentile of predicted R5 from the reference equation. There was a higher percentage of children with positive airway obstruction in children with asthma than in healthy controls (27.3% vs. 6.2%). Multivariate logistic regression analysis indicated that positive airway obstruction was a significant risk factor for the diagnosis of asthma (adjusted odds ratio (aOR), 6.245; 95% confidence interval (CI), 2.270-17.175). <I>Conclusion</I>. This study provided reference values for IOS in young Korean children and applied the reference values to evaluate children with asthma. We suggest the 95th percentile of predicted R5 as a cut-off value for positive airway obstruction, which may increase the risk for diagnosis of asthma.</P>
( Gwang Woong Go ),( Sangnam Oh ),( Miri Park ),( Gyoungok Gang ),( Danielle Mclean ),( Han Sul Yang ),( Min Ho Song ),( Young Hoon Kim ) 한국미생물 · 생명공학회 2013 Journal of microbiology and biotechnology Vol.23 No.11
In mice, supplementation of t10,c12 conjugated linoleic acid (CLA) increases liver mass and hepatic steatosis via increasing uptake of fatty acids released from adipose tissues. However, the effects of t10,c12 CLA on hepatic lipid synthesis and the associated mechanisms are largely unknown. Thus, we tested the hypothesis that gut microbiota-producing t10,c12 CLA would induce de novo lipogenesis and triglyceride (TG) synthesis in HepG2 cells, promoting lipid accumulation. It was found that treatment with t10,c12 CLA (100 μM) for 72 h increased neutral lipid accumulation via enhanced incorporation of acetate, palmitate, oleate, and 2- deoxyglucose into TG. Furthermore, treatment with t10,c12 CLA led to increased mRNA expression and protein levels of lipogenic genes including SREBP1, ACC1, FASN, ELOVL6, GPAT1, and DGAT1, presenting potential mechanisms by which CLA may increase lipid deposition. Most strikingly, t10,c12 CLA treatment for 3 h increased phosphorylation of mTOR, S6K, and S6. Taken together, gut microbiota-producing t10,c12 CLA activates hepatic de novo lipogenesis and TG synthesis through activation of the mTOR/SREBP1 pathway, with consequent lipid accumulation in HepG2 cells.